The new FAK inhibitor 10k inhibited the growth of NSCLC cell xenograft models, modulated FAK and downstream pathways favoring apoptosis induction, and enhanced the sensitivity to Osimertinib in vivo. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.